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Abstract
Background: Clostridium botulinum produces seven distinct serotypes of botulinum neurotoxins (BoNTs). The genes
encoding different subtype neurotoxins of serotypes A, B, F and several dual neurotoxin-producing strains have been
shown to reside on plasmids, suggesting that intra- and interspecies transfer of BoNT-encoding plasmids may occur. The
objective of the present study was to determine whether these C. botulinum BoNT-encoding plasmids are conjugative.
Methodology/Principal Findings: C. botulinum BoNT-encoding plasmids pBotCDC-A3 (strain CDC-A3), pCLJ (strain 657Ba)
and pCLL (strain Eklund 17B) were tagged with the erythromycin resistance marker (Erm) using the ClosTron mutagenesis
system by inserting a group II intron into the neurotoxin genes carried on these plasmids. Transfer of the tagged plasmids
from the donor strains CDC-A3, 657Ba and Eklund 17B to tetracycline-resistant recipient C. botulinum strains was evaluated
in mating experiments. Erythromycin and tetracycline resistant transconjugants were isolated from donor:recipient mating
pairs tested. Transfer of the plasmids to the transconjugants was confirmed by pulsed-field gel electrophoresis (PFGE) and
Southern hybridizations. Transfer required cell-to-cell contact and was DNase resistant. This indicates that transfer of these
plasmids occurs via a conjugation mechanism.
Conclusions/Significance: This is the first evidence supporting conjugal transfer of native botulinum neurotoxin-encoding
plasmids in C. botulinum, and provides a probable mechanism for the lateral distribution of BoNT-encoding plasmids to
other C. botulinum strains. The potential transfer of C. botulinum BoNT-encoding plasmids to other bacterial hosts in the
environment or within the human intestine is of great concern for human pathogenicity and necessitates further
characterization of these plasmids.
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Introduction
Clostridium botulinum is classified as an anaerobic, gram-positive,
sporeforming organism that produces an extraordinarily lethal
toxin designated botulinum neurotoxin (BoNT). BoNTs are
categorized into seven different serotypes listed A–G, and multiple
subtype BoNTs have been discovered and continue to be
identified, especially among serotypes A, B, E and F [1,2,3,4,5,6].
This highly heterogeneous species of C. botulinum is divided into
four groups based on metabolic, physiological and genetic
properties [7]. Historically, these neurotoxigenic clostridia have
been classified as C. botulinum based on their capacity to produce
BoNTs, but many researchers believe that the four clades
represent separate species of clostridia [2,8,9]. Group I contains
proteolytic strains of serotypes A, B and F, whereas Group II
encompasses nonproteolytic strains of serotypes B, E and F. Unlike
proteolytic strains, nonproteolytic strains lack the ability to digest
meat and milk proteins and rely on exogenous proteases for the
proteolytic nicking of the neurotoxin into its active di-chain form
[10]. C. botulinum serotype C and D strains are clustered in Group
III and strains of C. botulinum serotype G, also referred to as
Clostridium argentinense, are included in Group IV.
BoNT is the etiologic agent of botulism, a paralytic disease
resulting from the inhibition of neurotransmitter release at the
neuromuscular junction [11]. There are several forms of botulism,
and infant and foodborne represent the majority of botulism cases
reported in the U. S. [12]. Despite the unsavory reputation of
BoNTs as a deadly poison and as a potential bioterrorism agent,
their use in treatment for numerous hyperactive muscle disorders
has been widely demonstrated [13].
Although the genes encoding BoNTs of serotypes C, D and G
have been established to be associated with extrachromosomal
elements [14,15], the location of genes encoding serotypes A, B, E
and F were believed to be located on the chromosome from earlier
analyses of total genomic DNA [16]. Recently, strains of serotype
A, proteolytic and nonproteolytic strains of serotype B, and dual
neurotoxin-producing Ba, Ab and Bf strains have been shown to
harbor neurotoxin genes on very large plasmids [6,17,18].
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Bf subtypes analyzed thus far, it appears that both neurotoxin
genes are usually located on the same plasmid [6,18]. Plasmids
identified in proteolytic strains of C. botulinum range in size from
,150 to 270 kb and several plasmids found in serotypes A and B
and dual neurotoxin producing Ba and Bf strains have been shown
to be highly conserved, yet they carry different neurotoxin subtype
genes [6,8]. BoNT-encoding plasmids seem to be more prevalent
among strains of serotype B than other serotypes [6,18,19]. Unlike
the large plasmids observed in proteolytic serotype B strains,
plasmids found in nonproteolytic B strains are consistently smaller
(,48 kb) and share no homology with plasmids of proteolytic C.
botulinum strains [6,8].
These observations led to the hypothesis that BoNT-encoding
plasmids are the likely vehicles for the dissemination of neurotoxin
genes and are possibly transmissible at least between strains of C.
botulinum and perhaps to strains of closely related clostridial species
such as C. baratii and C. butyricum. Isolates of C. baratii and C.
butyricum have been found to produce BoNT/F and BoNT/E
respectively [12], but how these strains acquired the neurotoxin
genes is presently unknown.
To test the hypothesis that C. botulinum plasmids are transmis-
sible, the BoNT-encoding plasmids pBotCDC-A3 (proteolytic
subtype A3 strain CDC-A3), pCLJ (proteolytic subtype A4/
bivalent B strain 657Ba) and pCLL (nonproteolytic serotype B
strain Eklund 17B) were tagged using the ClosTron mutagenesis
system [20,21]. The BoNT/A3 subtype gene, bont/A3 (pBotCDC-
A3), the bivalent BoNT/B gene, bont/bvB (pCLJ), and the
nonproteolytic BoNT/B gene bont/npB (pCLL) were insertionally
inactivated by insertion of the group II intron containing the
erythromycin resistance marker. The tagged plasmids were used in
mating experiments with the recipient C. botulinum strain LNT01.
C. botulinum strain LNT01 is a transposon Tn916 mutant of the
parent C. botulinum subtype A1 strain 62A [22,23]. Upon
integration of the transposon the BoNT/A1 neurotoxin gene
cluster and regions flanking the cluster were deleted resulting in a
nontoxigenic C. botulinum strain that carries the tetracycline
resistance determinant. In this study we report the first
demonstration of native BoNT-encoding plasmid transfer from
an A3 subtype strain, an A4/bivalent B subtype strain and a
nonproteolytic serotype B strain to a nontoxigenic mutant of a
subtype A1 strain.
Results
Plasmids carrying neurotoxin genes have been identified in
some proteolytic and nonproteolytic C. botulinum strains of
serotypes A and B, and in bivalent subtypes Ba, Bf and Ab
[6,8,17,18,24]. We hypothesize that BoNT-encoding plasmids are
capable of intra- and interspecies transfer, since they are present in
a variety of proteolytic and nonproteolytic C. botulinum strains. To
test our hypothesis that C. botulinum BoNT-encoding plasmids are
transmissable, mating experiments were conducted between
donors harboring a BoNT-encoding plasmid and a nontoxigenic
C. botulinum strain LNT01 as the recipient. C. botulinum strains
CDC-A3 and 657Ba, which harbor large plasmids, pBotCDC-A3
(267 kb) and pCLJ (270 kb), respectively, were selected as donors
to represent proteolytic strains. As a representative of nonproteo-
lytic C. botulinum serotype B, strain Eklund 17B containing plasmid
pCLL (48 kb) was chosen as a donor strain. The recipient strain
LNT01 was selected because it is nontoxigenic, and it contains a
tetracycline resistance marker due to presence of the transposon
Tn916 on the genome [22,23]. To ascertain transfer of BoNT-
encoding plasmids from the donor to the recipient strain, the
plasmids were tagged with an erythromycin resistance gene using
the ClosTron mutagenesis system. Thus, positive selection of
transconjugants was facilitated by the presence of the tetracycline
resistance determinant in combination with erythromycin resis-
tance provided by the tagged plasmids.
Plasmid tagging using ClosTron
The neurotoxin genes, bont/A3 of plasmid pBotCDC-A3 (strain
CDC-A3), bont/bvB of plasmid pCLJ (657Ba), and bont/npB of
plasmid pCLL (strain Eklund 17B) were insertionally inactivated
using the ClosTron mutagenesis system [20,21]. The potential
intron target sites within each neurotoxin gene were identified
using the computer algorithm at the group II intron (TargeTron)
design site provided by Sigma-Aldrich (St. Louis, MO). The target
sites chosen for bont/A3, bont/bvB and bont/npB were between
nucleotides 580 and 581, 381 and 382, and 420 and 421 on the
sense strands, respectively. Each re-targeted intron was amplified
by PCR and cloned into the ClosTron vector pMTL007C-E2
between restriction sites HindIII and BsrGI [21] resulting in
constructs, pMTL007C-E2:Cbo:bont/A-580s, pMTL007C-
E2:Cbo:bont/bvB-381s, and pMTL007C-E2:Cbo:bont/npB-420s.
The constructs were transferred to their respective wild-type
strains CDC-A3, 657Ba and Eklund 17B by conjugation from the
E. coli donor strain CA434. Following matings, the cells were
plated onto agar containing thiamphenicol to select for C. botulinum
clones harboring the ClosTron vector. Thiamphenicol resistant
transconjugants of C. botulinum containing the ClosTron vector
were then plated onto agar supplemented with erythromycin for
selection of intron integrants, since the erythromycin resistance
gene is restored upon integration of the group II intron [20,21].
Next, erythromycin resistant clones were screened for the loss of
the intron vector by replica plating, then erythromycin resistant
and thiamphenicol sensitive clones were selected and further
analyzed by PCR to determine whether the intron had integrated
into its desired target site. The gene specific PCR primers (Table 1)
were designed to anneal to regions flanking the insertion site for
each neurotoxin gene in order to amplify the entire insertion
element. Insertion of the re-targeted introns into either the bont/
A3, bont/bvB or bont/npB genes was confirmed by PCR analysis
(Fig. 1). PCR amplification of the DNA from the wild type CDC-
A3 strain using the bont/A3 gene specific primers A3KMCT1 and
A3KMCT2 produced a PCR product of 1,264 bp (Fig. 1, Lane 1),
whereas a DNA fragment of 3,044 bp was observed in the CDC-
A3 transconjugant clones analyzed (Fig. 1, Lanes 2 and 3),
indicating integration of the intron element (,1.8 kb) into the
target gene. Similarly, amplification of the 657Ba and Eklund 17B
transconjugant clones (Fig. 1 Lanes 5 and 6, and Lanes 8 and 9,
respectively) using bont/bvB and bont/npB gene specific primers
yielded expected PCR products that exhibited an ,1.8 kb
increase in size compared to the PCR fragments generated from
the wild type 657Ba (Fig. 1, Lane 4) and Eklund 17B (Fig. 1, Lane
7). These results confirmed that the re-targeted introns containing
the erythromycin resistance determinant ermB were inserted into
the bont/bvB and bont/npb (Fig. 1). Furthermore, the PCR
fragments amplified from the tagged BoNT-encoding plasmids
were sequenced and it was confirmed that the introns had inserted
correctly into the chosen target sites within the neurotoxin genes in
all three plasmids.
To verify that the plasmids were tagged, pulsed-field gel
electrophoresis (PFGE) of nondigested DNA samples from the
wild type strains CDC-A3, 657Ba and Eklund 17B, and the clones
carrying the tagged plasmids pBotCDC-A3-Erm, pCLJ-Erm and
pCLL-Erm, was performed followed by Southern hybridization
analyses using probes specific to ermB and the respective
Plasmids in C.botulinum
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plasmid bands in all strains using the neurotoxin gene probes
(Fig. 2). Hybridization of the ermB probe was detected with the
tagged plasmid clones but not with the wild type strains, indicating
that the plasmids were successfully tagged with the ErmB-RAM.
The resultant strains with their tagged plasmids CDC-A3580s1
(pBotCDC-A3-Erm), 657BaCT4 (pCLJ-Erm) and Eklund
17BCT11 (pCLL-Erm) were used as the donors in the mating
experiments.
Mating experiments
Separate mixed plate matings between each donor strain, CDC-
A3580s1 (pBotCDC-A3-Erm), 657BaCT4 (pCLJ-Erm), and
Eklund 17BCT11 (pCLL-Erm) and recipient strains LNT01 and
Hall A-hyper/Tn916 mutant were performed inside an anaerobic
chamber on solid 4% agar TYG media for 12 h. Initially, strain
LNT01 was used as the recipient to determine if plasmids
pBotCDC-A3-Erm, pCLJ-Erm, and pCLL-Erm could be trans-
ferred to a recipient C. botulinum strain. Several mating experiments
were performed to optimize the mating conditions to establish the
transfer frequencies. Since similar transfer frequencies were
observed when matings were performed for 12 or 24 h (data not
shown); all subsequent bacterial mating experiments were
incubated for 12 h. The mating pairs between proteolytic strains
were performed at their optimal growth temperature of 37uC.
Matings of the nonproteolytic serotype B donor strain Eklund
17BCT11 and the recipient strain LNT01 were performed at
30uC, which is the optimal growth temperature for nonproteolytic
C. botulinum strains, since higher transfer frequencies were observed
at this temperature (data not shown). Three different donor to
recipient ratios (5:1, 1:1 and 1:5) were tested, the donor:recipient
(D:R) ratio of 1:1 yielded the highest transfer frequencies. After the
mating conditions were established in LNT01 the same experi-
mental parameters were used to evaluate the transfer frequencies
of C. botulinum plasmids into C. botulinum strain Hall A-hyper/Tn916
mutant.
Transconjugants were selected by plating the mating mixtures
onto TYG agar supplemented with erythromycin (selection of
Erm-plasmid) and tetracycline (selection of recipient strain LNT01
or Hall A-hyper/Tn916. To determine the number of donors and
recipients the mating mixtures were also plated onto TYG
containing either erythromycin (donors) or tetracycline (recipients).
The number of donor cells and recipients varied with respect to
the mating pairs (Table 2). The transfer frequency was calculated
as the number of transconjugants per recipient or donor
depending on which strain had the highest CFU/ml.
The transfer frequency values are displayed in Table 2. Overall,
the plasmid transfer frequencies were lower than those reported for
plasmids found in strains of Clostridium perfringens [25,26,27]. The
conjugation frequencies for pBotCDC-A3-Erm and of pCLJ-Erm
increased markedly when Hall A-hyper/Tn916 w a su s e da st h e
recipient. Similar conjugation frequencies of plasmid pCLL from the
nonproteolytic strain Eklund 17B were observed when either strain
LNT01 or Hall A-hyper/Tn916 was used as recipient (Table 2).
Pre-incubation of the donor cells with DNaseI, by combined
addition of DNaseI to the agar medium and to the mating
mixtures did not inhibit plasmid transfer, and the transfer
frequencies were similar to that of matings in which DNaseI was
not added. Furthermore, no transductants were obtained in
matings performed with the filtered culture supernatants of each
donor strain and the whole cell culture of the recipient strain
LNT01. Importantly, no transconjugants were obtained when
matings were performed in which the donors and recipients were
separated by a 0.45 mm nitrocellulose membrane.
Figure 1. Confirmation of tagging C. botulinum BoNT-encoded
plasmids pBotCDC-A3-Erm (strain CDC-A3), pCLJ-Erm (strain
657Ba) and pCLL-Erm (strain Eklund 17B) by PCR analysis. PCR
products of wild-type C. botulinum strains CDC-A3 (Lane 1), 657Ba (Lane
4) and Eklund 17B (Lane 7) and two erythromycin resistant,
thiamphenicol sensitive clones of each of CDC-A3 (Lanes 2 and 3),
657Ba (Lanes 5 and 6) and Eklund 17B (Lanes 8 and 9) strains; 1 kb Plus
ladder (Invitrogen) (Lane M).
doi:10.1371/journal.pone.0011087.g001
Table 1. Oligonucleotide primers used in this study.
Oligonucleotide Primer Sequence (59 -3 9)
580|581s-IBS AAAAAAGCTTATAATTATCCTTACA-
GATCTTACATGTGCGCCCAGATAGGGTG
580|581s-EBS1d CAGATTGTACAAATGTGGTGATAACAGATA-
AGTCTTACATTTTAACTTACCTTTCTTTGT
580|581s-EBS2 TGAACGCAAGTTTCTAATTTCGGTTATC-
TGTCGATAGAGGAAAGTGTCT
381|382s-IBS AAAAAAGCTTATAATTATCCTTAGTTCCCCT-
CGAAGTGCGCCCAGATAGGGTG
381|382s-EBS1d CAGATTGTACAAATGTGGTGATAACAGATAA-
GTCCTCGAAGATAACTTACCTTTCTTTGT
381|382s-EBS2 TGAACGCAAGTTTCTAATTTCGATTGGAAC-
TCGATAGAGGAAAGTGTCT
420|421S-IBS AAAAAAGCTTATAATTATCCTTAACTGTCAA-
TAAAGTGCGCCCAGATAGGGTG
420|421S-EBS1d CAGATTGTACAAATGTGGTGATAACAGATA-
AGTCAATAAATTTAACTTACCTTTCTTTGT
420|421S-EBS2 TGAACGCAAGTTTCTAATTTCGATTACAG-
TTCGATAGAGGAAAGTGTCT
EBS Universal CGAAATTAGAAACTTGCGTTCAGTAAAC
A3KMCT1 GAGATCCTGTAAATGGTGTTGATATTGC
A3KMCT2 GGTATTATCCCTCTTACACATAGCAGC
BVBFCT4 CAAACAATGATCAAGTTATTTAATAG
BVBRCT4 TCATTTAAAACTGGCCCAGG
NPBFCT11 CAAATCAAAACCATTGGGTGAAAAG
NPBRCT11 CTGGACAAAATTTCATTTGCATTATACCCC
AnyBF CAGGAGAAGTGGAGCGAAAAAAAG
AnyBR TGGTAAGGAATCACTAAAATAAGAAGC
Erm-F CCGATACCGTTTACGAAATTGGAACAGG
Erm-R TTATTTCCTCCCGTTAAATAATAGATAACT
pMTL007-R1 AGGGTATCCCCAGTTAGTGTTAAGTCTTGG
doi:10.1371/journal.pone.0011087.t001
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PFGE was performed using nondigested samples and samples
digested with restriction enzymes designed to linearize each BoNT-
encoding plasmid. PFGE analysis of digested samples allowed us to
use the unique restriction bandingpatterns of the strains as a genetic
screen to visually determine whether the plasmids were transferred
to the recipient strains. PFGE analyses of the recipient LNT01,
donor strains and LNT01 transconjugants from three separate
matings are shown in Figures 3–5. LNT01 (recipient), wild type and
plasmid-tagged donor strains, and three clones of each transconju-
gant all exhibited unique restriction banding patterns when digested
with SmaI, XhoIo rNarI. PFGE followed by Southern hybridization
analyses using the ermB probe (intron probe) and the appropriate
neurotoxin gene probes showed that the tagged plasmids were
transferred to the recipient strains (Figures 3–5).
Transfer of pBotCDC-A3-Erm from CDC-A3 (donor) to LNT01
(recipient) is shown in Fig. 3. When PFGE is performed on
nondigested C. botulinum DNA samples most of the DNA remains
trapped in the wells because large circular DNA molecules that are
nicked or enzymatically relaxed fail to enter the gel matrix [28].
Linear forms of plasmids are able to migrate through the gel to a
position which corresponds to their linear size relative to a reference
marker [28]. In addition, a small portion of sheared chromosomal
DNA migrating a short distance from the well position is frequently
observed in PFGE analysis of nondigested clostridial DNA [17]. The
DNA restriction banding pattern of the wild type strain LNT01 (lane
7A) digested with SmaI was identical to that of the transconjugants
(lanes 10–12A), except that the banding pattern of all transconjugant
clones contained an additional band of ,270 kb. This band
corresponds by size to the plasmid, pCDC-A3-Erm in the donor
strain (A-lanes2,3 and 8,9).This,27 0kbbandobse rv edindige st e d
(lanes 10–12) and nondigested (lanes 4–6) samples of the transconju-
gants hybridized with both bont/A3 (C: lanes 4–6, 10–12) and ermB
probes (B: lanes 4–6, 10–12). These results confirmed the transfer of
the tagged plasmid containing the intron interrupted bont/A3 gene.
The sameplasmid band in the donor strains hybridized with the bont/
A3 probe (C: lanes 2, 3, 8, 9), but only the tagged donor hybridized
with the ermB probe (B: lanes 3 and 9). No hybridization signals were
detected with either probe in the recipient strain LNT01. PFGE of
digested samples of the transconjugant and donor strains (A: lanes 8–
12) showed an increase in the intensity of the ,270 kb band in the
ethidium bromide stained gel as well as produced stronger
hybridization signals with the neurotoxin gene (C: lanes 8–12) and
ermB (B: lanes 9–12) probes, while the hybridization signals at the well
positions decreased. This indicated that the plasmid was linearized by
the restriction enzyme and migrated into the gel.
Similarly, transfer of the ,270 kb plasmid, pCLJ-Erm, from
the donor strain 657BaCT4 to LNT01 (Fig. 4), and the ,48 kb
Figure 2. Confirmation of tagging C. botulinum BoNT-encoding plasmids pBotCDC-A3-Erm (strain CDC-A3), pCLJ-Erm (strain 657Ba)
and pCLL-Erm (strain Eklund 17B) by PFGE and Southern hybridization analysis. (B) Ethidium bromide stained PFGE of nondigested DNA
samples from C. botulinum strains: wild type CDC-A3 (Lane 1), CDC-A3580s1 (Lane 2), wild type 657Ba (Lane 3), 657Ba-CT4 (Lane 4), wild type Eklund
17B (Lane 5) and Eklund17B-CT11 (Lane 6); Lambda PFG Marker (Lane M), (New England Biolabs). The position of BoNT-encoding plasmids is indicated
with arrows. (A) Southern hybridization with the bont/A3 probe (Lanes 1 and 2); the bont/bvB probe (Lanes 3 and 4) and the bont/npB probe (Lanes 5
and 6); (C) Southern hybridization with the ermB probe. PFGE conditions: 6V/cm, 12uC, 1–20 s pulse time, 24 h.
doi:10.1371/journal.pone.0011087.g002
Table 2. Transfer of C. botulinum BoNT-encoding plasmids to
recipient strains LNT01 and Hall A-hyper/Tn916.
Transfer Frequency
Recipient
Donor Plasmid LNT01 Hall A-hyper/Tn916
CDC-A3580 pBotCDC-A3-Erm 1.5610
2861.2610
28a 1.8610
2669.4610
27b
657Ba-CT4 pCLJ-Erm 1.4610
2661.1610
26a 1.7610
2561.2610
25a
Eklund 17BCT11 pCLL-Erm 1.5610
2761.4610
27a 4.5610
2762.8610
27a
Transfer frequencies were calculated as the number of tranconjugants per
arecipient or
bdonor and are reported as the averages of at least three replicate
experiments.
doi:10.1371/journal.pone.0011087.t002
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Southern hybridization analysis. (A) Ethidium bromide stained PFGE of C. botulinum DNA samples: SmaI digested DNA of C. botulinum strain
LNT01 (Lanes 1 and 7), CDC-A3 wild type (Lanes 2 and 8), CDC-A3580s1 (Lanes 3 and 9), and LNT01 transconjugants (pBotCDC-A3-Erm) (Lanes 4–6
and 10–12); Lanes 1–6, nondigested DNA samples; Lanes 7–12, SmaI digested DNA samples. Lambda PFG Marker (Lane M), New England Biolabs. The
position of the pBotCDC-A3 plasmid is indicated with an arrow. Southern hybridization with: (B) the ermB probe, and (C) the bont/A3 probe. PFGE
conditions: 6V/cm, 12uC, 1–26 s pulse time, 24 h.
doi:10.1371/journal.pone.0011087.g003
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11087Figure 4. Confirmation of plasmid pCLJ-Erm transfer from C. botulinum strain 657BaCT4 to strain LNT01. (A) Ethidium bromide stained
PFGE of C. botulinum strains: LNT01 (Lanes 1 and 7), wild type strain 657Ba (Lanes 2 and 8); 657BaCT4 (Lanes 3 and 9) and LNT01 transconjugants
(pCLJ-Erm) (Lanes 4–6 and 10–12); Lanes 1–6, nondigested DNA samples; Lanes 7–12, XhoI digested DNAsamples. Lambda PFG Marker (Lane M), New
England Biolabs. The position of the pCLJ plasmid is indicated with an arrow. Southern hybridization with: (B) the ermB probe and (C) the bont/bvB
probe. PFGE conditions: 6V/cm, 12uC, 1–26 s pulse time, 24 h.
doi:10.1371/journal.pone.0011087.g004
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confirmed (Fig. 5). Furthermore, transfer of plasmids
pBotCDC-A3-Erm, and pCLJ-Erm to Hall A-hyper/Tn916 was
also confirmed by PFGE and Southern hybridization analyses
(Fig. 6).
Plasmid Alignments
The genome alignment tool Mauve [29] was used to generate
global alignments of C. botulinum plasmid pCLL (strain Eklund 17B)
and C. perfringens plasmid pCP13 (strain 13). Alignment of plasmids
pCLL and pCP13 (Fig. 7) revealed 16 locally collinear blocks (LCBs)
Figure 5. Confirmation of plasmid pCLL-Erm transfer from C. botulinum strain Eklund 17BCT11 to strain LNT01. (A) Ethidium bromide
stained PFGE of C. botulinum strains: LNT01 (Lanes 1 and 7), wild type strain Eklund 17B (Lanes 2 and 8); Eklund 17BCT11 (Lanes 3 and 9) and LNT01
transconjugants (pCLL-Erm) (Lanes 4–6 and Lanes10–12). Lanes 1–6, nondigested DNA samples; Lanes 7–12, NarI digested DNA samples. Lambda PFG
Marker (Lane M), New England Biolabs. The position of the pCLL plasmid is indicated with an arrow. Southern hybridization with: (B) the ermB probe,
and (C) the bont/npB probe. PFGE conditions: 6V/cm, 12uC, 1–20 s pulse time, 24 h.
doi:10.1371/journal.pone.0011087.g005
Plasmids in C.botulinum
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in gold(Fig.7)encompassed aregionof11 ORFswhichexhibitedthe
highest degree of sequence homology with similar ORFs found on
plasmid pCP13. Mauve was also used to generate global alignments
of pCLL and C. perfringens plasmids pCW3, pCP8533etx, and two
contigs of C. perfringens type D strain JGS1721 (gcon-
tig_1108490430283 and gcontig_1108490430999). The alignments
revealed several locally collinear blocks (LCBs) with at least some
portion of them found in the C. perfringens plasmids (Fig. 8). Two
neighboring LCBs shown ingreen and bluewere of particular interest
because they shared homology with the conjugative C. perfringens
plasmids. The region that contained the tcp locus common to C.
perfringens conjugative plasmids is represented by the LCB colored
blue (Fig. 8). The corresponding blue LCB observed in pCLL shares
some sequence homology with this region as indicated in Fig. 8,
however this region is truncated. The green LCB of plasmid pCLL
contains a gene that encodes for a putative type IV secretion system
protein VirD4 (pCLL_0005). Comparison of homologous ORFs of
pCLL and C. perfringens plasmids is presented in Table 3.
Discussion
Early studies attempting to demonstrate plasmid-associated
BoNT genes were unsuccessful, except for discovery of the
plasmid-borne BoNT/G gene [15]. The recent finding of plasmids
in C. botulinum serotypes A and B housing BoNT/A, BoNT/B or
both BoNT/A and BoNT/B genes [17,24] prompted surveys of
serotype B strains [18,19] and dual neurotoxin C. botulinum strains
Figure 6. Confirmation of plasmid pCLK-Erm and pCLJ-Erm transfer to C. botulinum Hall A-hyper-Tn916 mutant strain. (A) Ethidium
bromide stained PFGE of C. botulinum strains: wild type Hall A-hyper (Lane 1), Hall A-hyper/Tn916 mutant (Lane 2); Hall A-hyper/Tn916/pBotCDCA3-
Erm (Lane 3); CDC-A3 plasmid-cured (Lane 4); wild type CDC-A3 (Lane 5). (D) Ethidium bromide stained PFGE of C. botulinum strains: wild type Hall A-
hyper (Lane 6), Hall A-hyper/Tn916 mutant (Lane 7); Hall A-hyper/Tn916/pCLJ-Erm (Lanes 8 and 9); 657Ba-CT4 (Lane 10); wild type Hall A-hyper (Lane
11). Nondigested DNA and SmaI digests were loaded on the gels as indicated below the lanes. Lambda PFG Marker (Lane M), New England Biolabs.
The position of the pBotCDC-A3 and pCLJ plasmids is indicated with arrows. Southern hybridization with: (B and E) the ermB probe; and (C and F) the
tet probe. PFGE conditions: 6V/cm, 12uC, 1–26 s pulse time, 24 h.
doi:10.1371/journal.pone.0011087.g006
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have invigorated interest in the field of plasmid biology in C.
botulinum. The primary hypothesis of the present study was to
determine whether the plasmids encoding BoNT can be
transferred to other C. botulinum strains.
Here, we have demonstrated the transfer of the native BoNT-
encoding plasmids pBotCDC-A3 and pCLJ from two proteolytic
strains, and pCLL from a nonproteolytic strain, to other proteolytic
C. botulinum strains. Our data strongly supports that the mechanism
of plasmid transfer is conjugation. Transductants were not obtained
when the recipient cells were incubated with filtered donor culture
supernatants, supporting that bacteriophages were not involved in
BoNT gene transfer. Furthermore, since BoNT gene transfer was
not inhibited by the addition of DNaseI, and no transconjugants
wereobtained duringmatings in which the donorand recipient cells
were separated by a 0.45 mm filter, we conclude that cell-to-cell
contactisrequiredforthetransferoftheseplasmids.Hence,plasmid
transfer appears to be due to conjugation or a conjugation-like
mechanism rather than by transformation.
Prior to this study, C. perfringens was the only Clostridium
described to harbor plasmids capable of intraspecies conjugative
transfer [25,26,27,30,31]. In this study, conjugative transfer of
plasmid pCLL from the nonproteolytic C. botulinum serotype B
strain Eklund 17B to a proteolytic C. botulinum strain, supports
interspecies transfer since proteolytic and nonproteolytic groups
have long been considered to comprise different Clostridium
species based on different genomic, genotypic and phenotypic
characteristics [2,9].
Intraspecies conjugal transfer of plasmids in C. perfringens has
been reported to be a highly efficient process with conjugation
frequencies of 10
21 to 10
22 transconjugants per donor [25,26,27].
Conversely, the conjugation frequencies for the C. botulinum
plasmids tested in this study were much lower ranging from
10
25 to 10
28 (Table 2). C. botulinum strain LNT01 was initially
selected as a recipient, since it is nontoxigenic and contained the
tetracycline resistance marker for positive selection of transconju-
gants. Although each of the plasmids was successfully transferred
to LNT01, we observed a decrease in the number of donor cells
during matings. For example, an approximately 4-log reduction in
the number of CFU/ml of donors CDC-A3580s1 and 657BaCT4-
2 was observed during matings with LNT01. A possible
explanation may be that strain LNT01 produces a bacteriocin
(unpublished data) that could inhibit the growth or kill the donor
cells. C. perfringens strain F4969 was also reported to produce a
bacteriocin which interfered with the transfer of plasmid
pMRS4969 from this strain to the recipient C. perfringens strain
because the bacteriocin greatly inhibited or killed the recipient
cells [27]. Interestingly, only a 1–2 log reduction of donor (CFU/
ml) was observed when the nonproteolytic C. botulinum strain
Eklund 17BCT11 was used as the donor. To further investigate if
a plasmid-endoded bacteriocin affected transfer efficiencies,
another C. botulinum strain (Hall A-hyper/Tn916) that does not
contain any plasmids nor a plasmid encoded-bacteriocin similar to
those identified in C. botulinum strains ATCC 3502 (Acc.
No. AM412318) [32] and 213B [33], was tested as a recipient.
The plasmid transfer frequency of pCLJ and pBotCDC-A3 into
Hall A-hyper/Tn916 increased by at least a log compared to that of
LNT01 as a recipient while the transfer frequency of pCLL from
the nonproteolytic strain Eklund 17B was similar when both
recipients were tested (Table 2). Further studies are required to
elucidate the factors and mechanisms affecting conjugal transfer
and recipient stability of BoNT-encoding plasmids.
Figure 7. Plasmid alignment of pCLL (C. botulinum strain Eklund 17B) and pCP13 (C. perfringens strain 13). The alignment has two
panels, one for each complete plasmid: pCP13 [top position] and pCLL [bottom position]. The top portions of the panels are composed of colored
segments corresponding to the boundaries of locally collinear blocks (LCBs) with lines connecting the homologous blocks in each plasmid. LCBs
below a plasmid’s centerline are in the reverse complement orientation relative to the reference plasmid (pCP13). The lower portion of the panels
represent the predicted open reading frames (ORFs) for the corresponding segments of double stranded DNA with ORFs on top representing top
strand and below (bottom strand).
doi:10.1371/journal.pone.0011087.g007
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on MLST [34] and PFGE analyses [6], and it is highly likely that the
plasmids are identical in both strains. The nucleotide sequences of
pCLK (strain Loch Maree, A3), pCLJ (strain 657Ba, A4) and pCLL
(strain 17B) genome sequences have been deposited in GenBank [24].
Although plasmids pCLK and pCLJ share significant sequence
homology, the sequence of plasmid pCLL is unrelated to pCLJ and
pCLK [6,8]. Detailed sequence analysis of the botulinum gene
clusters of plasmids pCLK and pCLJ have been performed, but little
emphasis has been given to the functions of other plasmid genes [24].
Most of the ORFs of these plasmids are described as putatively
encoding hypothetical or conserved hypothetical proteins. The
mechanism for plasmid replication is unknown, because gene
homologues involved in typical rolling-circle or theta replication
have not been identified on these plasmids [24]. Similarly, the
mechanism of plasmid transfer is also unknown, but genes
homologous in plasmids pCLK and pCLJ that may be involved in
plasmid transfer are suggested by the genome annotations. For
example, TraK analogs (CLK_A0294; CLJ_A0213) and TraG/D
(CLK_A0293; CLJ_A0212) flanked by hypothetical ORFs, as well as
genes that encode for putative type II and type IV secretion system
proteins, such as pili, have been described.
Plasmid pCLL of nonproteolytic C. botulinum serotype B strain
Eklund 17B is ,48 kb in size and contains 54 putative ORFs. As
mentioned above pCLL does not exhibit homology with sequenced
plasmids in proteolytic C. botulinum strains. Therefore, homology
searches of pCLL were performed with genome sequences of other
clostridial species. Initially, a nucleotide sequence alignment of
pCLL with pCP13 of C. perfringens strain 13 was performed using
Mauve. Surprisingly, this analysis identified regions of homology
between pCLL and pCP13, which are graphically displayed as
colored locally collinear blocks (LCBs) (Fig. 7). More detailed
BLAST analyses revealed eleven ORFs within the gold-colored
LCB (CLL_0004 to CLL_0017) with a range of identity from 34 to
67% with ORFs of plasmid pCP13 (Table 3). However, the
function(s) of the identified ORFs in both plasmids is unknown,
because these putative gene products are described as hypothetical
or conserved hypothetical proteins. Considering that pCP13 is not a
conjugative plasmid, further sequence analyses were performed
between pCLLandcompleted sequencesofconjugativeC. perfringens
plasmids and draft genome sequences of several C. perfringens strains.
Interestingly, two conjugative C. perfringens plasmids pCW3 and
pCP8533etx as well as two contigs representing potential plasmids
in a type D strain were identified by Mauve to contain regions
homologous to pCLL (Fig. 8). Mauve revealed two LCBs colored
green and blue, which represented regions of pCLL homologous to
the C. perfringens nucleotide sequences. The blue LCB encompassed
the tcp (transfer of clostridium plasmids) locus common to
conjugative C. perfringens plasmids [31]. Although plasmid pCLL
does not seem to contain the entire tcp locus it does carry genes that
encode for proteins that exhibit 61% (CLL_0011) identity to TcpG
(CPC_A0146 of C. perfringens C strain JGS1495) [31]. The ORF
pCLL_0005 (a putative VirD4 homolog) in the green LCB showed
51% identity to CJD_A0258 (a putative VirD4 component) of C.
perfringens typeD strainJGS 1721.Further BLAST analysesrevealed
that C. perfringens type D strain JGS 1721 contained several ORFs
with identities ranging from 37%–51% with ORFs of pCLL
(Table 3). C. perfringens type D strains carry several plasmids ranging
Figure 8. Plasmid alignment of pCLL (C. botulinum strain Eklund 17B), pCW3 (C. perfringens strain CW92), contigs 1108490430999
and 1108490430283 (C. perfringens type D strain JGS1721) and pCP8533etx (C. perfringens type B strain NCTC8533B4D). The
alignment has five panels, one for each plasmid. The top portions of the panels are composed of colored segments corresponding to the boundaries
of locally collinear blocks (LCBs) with lines connecting the homologous blocks in each plasmid. LCBs below a plasmid’s center line are in the reverse
complement orientation relative to the reference plasmid (pCLL).
doi:10.1371/journal.pone.0011087.g008
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(plc gene) and epsilon-toxin (etx gene). The epsilon toxin is ranked
third in potency following BoNTs and tetanus neurotoxin [35]. C.
perfringens type D strains that produce alpha-toxin and epsilon-
toxins, but not the enterotoxin (cpe gene) or the beta 2 toxin (cpb2
gene) have been reported to carry the etx gene on a plasmid of
,48 kb[36].Theetxplasmid inC.perfringenstypeD strainJGS1721
also contains the tcp locus [36]. The draft genome sequence of C.
perfringens strain JGS 1721 consists of 221 contigs. The pCLL ORFs
shared homology with 16 and 8 ORFs within two of these contigs,
gcontig_1108490430999 and gcontig_1108490430283, respective-
ly. Interestingly, gcontig_1108490430283 carries the genes that
encode for etx and the tcp locus.
Overall, homology searches revealed that BoNT-encoding
plasmid pCLL of the nonproteolytic C. botulinum strain exhibited
some degree of homology with both conjugative and nonconju-
gative plasmids in C. perfringens. These results are interesting from
an evolutionary perspective, and may warrant further studies on
horizontal gene transfer in pathogenic clostridial species.
The presence of BoNT genes on conjugative plasmids in both
proteolytic and nonproteolytic strains of C. botulinum is highly
significantand could facilitatethedisseminationofneurotoxin genes
to other species of clostridia. It is conceivable that BoNT-encoding
plasmids were involved in the transfer of BoNT/E and BoNT/F
genes to C. butyricum and C. baratii. Studies have shown that C.
butyricum does not possess BoNT-encoding plasmids [37], but
considering the suggested mobility of the neurotoxin gene clusters
[8,18,24],plasmidscouldbeutilized bythe organismtomobilizethe
neurotoxin gene cluster into another bacterial host. Whether or not
the plasmid backbones are integrated into the newly acquired host
or simply lost is unknown and requires further investigation.
In summary, this study demonstrates for the first time the
conjugative transfer of proteolytic and nonproteolytic C. botulinum
plasmids encoding BoNT genes to other proteolytic C. botulinum
strains. This work is highly significant in the evolution of
pathogenesis of clostridia. Since BoNT is the most potent toxin
known, BoNT gene transfer to other bacteria could lead to the
generation of new pathogens of high impact, such as emergence of
new BoNT-forming clostridia with resistant phenotypes, and strains
with higher spore heat resistance than C. botulinum. The finding that
pCLL of the nonproteolytic C. botulinum serotype B strain contains
gene regions that are homologous with plasmids in C. perfringens is
intriguing and illustrates the potential transfer of plasmids to other
clostridial species. Further workis neededto elucidate the molecular
mechanisms of BoNT-encoding plasmid transfer, their mainte-
nance, and gene expression. The study of the population dynamics
of plasmid dissemination to other bacterial hosts in the environment
or the human and animal intestine is of concern to human and
animal pathogenesis and warrants further study.
Materials and Methods
Bacterial Strains
Proteolytic Clostridium botulinum strains CDC-A3 (BoNT subtype
A3), 657Ba (subtype A4/bivalent B), LNT01 (nontoxigenic,
subtype A1), Hall A-hyper (subtype A1) and nonproteolytic C.
botulinum serotype B strain Eklund 17B were obtained from the
Johnson laboratory culture collection. C. botulinum strain CDC-A3
was originally obtained from the Centers for Disease Control and
Prevention (CDC) (Atlanta, GA). MLST and PFGE analyses
indicated it was genetically identical to subtype A3 strain Loch
Maree [34]. C. botulinum strain 657Ba was isolated from a case of
infant botulism in 1976 [38]. C. botulinum strain Eklund 17B was
isolated from marine sediments off the coast of Washington [39].
C. botulinum strain LNT01 is a nontoxigenic Tn916 mutant of the
parent strain 62A (subtype A1) [22,23]. Hall A-hyper is a well-
characterized subtype A1 strain, which produces high quantities of
BoNT/A1 [40]. Escherichia coli strains DH10B and CA434 were
used for cloning, maintenance and conjugal transfer of the re-
targeted ClosTron vectors. All C. botulinum strains were maintained
as frozen stocks at 280uC in TPGY broth (50 g/liter trypticase
peptone, 5 g/liter Bacto peptone, 4 g/liter D-glucose, 20 g/liter
yeast extract, 1 g/liter cysteine - HCl, pH 7.4) containing 20%
glycerol. Bacterial strains were subsequently cultured anaerobical-
ly in TPGY. Mating experiments were conducted on nonselective
TYG (30 g/liter Bacto Tryptone, 20 g/liter yeast extract, 1 g/liter
sodium thioglycollate) (4% agar) media and then spread plated
onto selective TYG (1.5% agar) plates supplemented with the
appropriate antibiotics. Antibiotics were used at the following
concentrations: cycloserine (250 mg/ml), sulfamethoxazole (76 mg/
ml), thiamphenicol (15 mg/ml), tetracycline (10 mg/ml), erythro-
mycin (2.5 mg/ml), chloramphenicol (25 mg/ml in agar plates and
12.5 mg/ml in broth). All bacterial media components and
chemicals were purchased from Becton Dickinson Microbiology
Systems, Sparks, MD and Sigma-Aldrich, St. Louis, MO.
Plasmid tagging using ClosTron
The ClosTron mutagenesis system [20,21] was used to
insertionally inactivate bont/A3, bont/bvB and bont/npB of plasmids
pBotCDC-A3 (strain CDC-A3), pCLJ (strain 657Ba) and pCLL
(strain Eklund 17B), respectively. The computer algorithm
available through the Targetron (group II intron) Design Site
(http://www.sigma-genosys.com/targetron/) was used to design
the PCR primers listed in Table 1 for intron re-targeting of the
selected genes bont/A3, bont/bvB and bont/npB. Primers IBS-
580|581s, EBS1d-580|581s, IBS-381|382s, EBS1d-381|382s,
IBS-420|421s, EBS1d-420|421s and EBS Universal (Table 1)
were purchased from Sigma-Aldrich (St. Louis, MO). A two-step
PCR reaction was used to generate the 350 bp re-targeted intron.
The first step included two separate PCR reactions: one
containing the IBS and EBS universal primers and the other
containing the EBS2 and EBS1d primers. The intron PCR
template supplied in the Targetron Gene Knockout System kit
(Sigma-Aldrich, St. Louis, MO) was used as the DNA template.
Five microliters of each PCR product obtained in the first PCR
reactions were combined and used as the template in a second
PCR reaction containing the IBS and EBS1d primers. PCR
reactions were performed using the GeneAmp High Fidelity PCR
system (Applied Biosystems, Foster City, CA) under the following
conditions: initial hold at 94uC for 30s; followed by 20 cycles of 15s
of denaturation at 94uC, 30s of primer annealing at 55uC, and 30s
of extension at 72uC and then a final 7 min step at 72uC.
The resulting PCR products of 350 bp representing the re-
targeted intron were purified by gel extraction (Qiagen) and
cloned into the vector pMTL007C-E2 [21] using restriction
endonucleases HindIII and BsrGI by standard cloning techniques
[41]. Transformants containing modified ClosTron vectors were
selected from E. coli strain DH10B based on chloramphenicol
resistance, and plasmid DNA was isolated using a plasmid
minipreparation kit (Fermentas Inc., Glen Burnie, MD). Plasmids
were analyzed by restriction analysis with HindIII and BsrGI, and
the correct sequence of the intron was verified by sequencing using
the primer pMTL007-R1 (Table 1). The sequencing primer was
purchased from Integrated DNA Technologies, Inc. (Coralville,
IA). Sequencing reactions were performed using an ABI PRISM
BigDye Cycle Sequencing Ready Reaction kit (Applied Biosys-
tems, Foster City, CA) then purified according to manufacturer’s
instructions, and analyzed at the University of Wisconsin
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analyzed with sequence analysis software VectorNTI (Invitrogen,
Carlsbad, CA). Plasmid DNA from one of the clones containing
the correct intron sequence for targeting each BoNT gene was
named pMTL007C-E2:Cbo:bont/A-580s (bont/A3), pMTL007C-
E2:Cbo:bont/bvB-381s (bont/bvB), and pMTL007C-E2:Cbo:bont/
npB-420s (bont/npB) and was transformed into the E. coli
conjugation donor strain CA434.
Plasmids pMTL007C-E2:Cbo:bont/A-580s, pMTL007C-
E2:Cbo:bont/bvB-381s, and pMTL007C-E2:Cbo:bont/npB-420s
were transferred to C. botulinum strains CDC-A3, 657Ba and
Eklund 17B, respectively, by conjugation from E. coli donor strain
CA434 as previously described [20]. After mating, the bacterial
mixture was scraped off of the mating plates, resuspended in
16PBS (phosphate buffered saline), serially diluted and spread
plated onto TYG agar supplemented with cycloserine, sulfameth-
oxazole (selection of C. botulinum) and thiamphenicol (selection for
the vectors). Thiamphenicol resistant colonies were purified by re-
streaking onto fresh TYG agar supplemented with thiamphenicol.
Individual colonies were re-suspended in 16PBS, serially diluted
and plated onto TYG agar containing erythromycin to select for
the presence of the spliced Erm-RAM indicating intron integra-
tion. Erythromycin resistant colonies were re-streaked onto fresh
TYG agar containing erythromycin. Erythromycin resistant clones
were replica plated onto TYG containing thiamphenicol to verify
plasmid loss by a thiamphenicol sensitive phenotype.
Chromosomal DNA was isolated from randomly selected
erythromycin resistant, thiamphenicol sensitive clones as well as
from wild type C. botulinum strains using the ChargeSwitch gDNA
kit (Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Screening of the clones was performed by PCR using
the gene specific primers A3KMCT1, A3KMCT2 (bont/A3),
BVBFCT4, BVBRCT4 (bont/bvB), and NPBFCT11, NPBRCT11
(bont/npB) (Table 1) designed to anneal to regions flanking the site
of intron integration. PCR was performed with AmpliTaq High
Fidelity DNA polymerase, buffer and dNTPs (Applied Biosystems,
Foster City, CA) using a GeneAmp PCR System 9700 (Applied
Biosystems) according to manufacturer’s instructions. PCR
primers were purchased from Integrated DNA Technologies,
Inc. (Coralville, IA). PCR products were visualized on 1% Tris-
acetate-EDTA gels, stained with ethidium bromide and photo-
graphed using a Gel Imaging System (BioRad, Hercules, CA) with
UV transillumination. PCR products were purified using a PCR
purification kit (Qiagen, Valencia, CA) according to manufactur-
er’s instructions. The nucleotide sequences of the PCR fragments
generated from the wild type and the transconjugant clones were
determined using the same primers as for the amplication of the
DNA fragments (Table 1). The nucleotide sequences were
analyzed as described above.
Tn916 Mutagenesis
C. botulinum strain Hall A-hyper was chosen for Tn916
mutagenesis to generate tetracycline resistant strains. The genome
sequence of Hall A-hyper is completed (GenBank Acc: CP000727).
This strain does not contain any plasmids. Tn916 mutant clones of
Hall A-hyper were generated using the methods for Tn916
mutagenesis described in Lin and Johnson [22]. This strain
containing a tetracycline resistance marker was used as an
alternative recipient in the bacterial mating experiments with
donors CDC-A3 and 657Ba.
Mating experiments
Donor and recipient strains were inoculated into TPGY broth
from frozen stocks and incubated anaerobically overnight. The
strains were subcultured into TPGY containing 2.5 mg/ml
erythromycin (donors) and 10 mg/ml tetracycline (recipients).
The donors and recipients were passed again in TPGY broth
supplemented with antibiotics and incubated anaerobically for
12 h. Each strain was serially diluted to ,10
4 to 10
5 CFU/ml in
TPGY broth and incubated until an OD600nm of 0.6 to 0.8.
Matings between donors and recipients were performed on solid
nonselective 4% TYG agar. Three different donor to recipient
ratios (5:1, 1:1 and 1:5) were tested. Aliquots of 1 ml or 200 mlo f
donor (D) and recipient (R) cells were centrifuged at 3,0006g for
5 min and resuspended in 200 ml of recipient or donor cells,
respectively, and spread plated onto 4% TYG agar. The mating
plates were incubated right side up for 12 h at 37uCo r3 0 uC
depending on the optimal growth temperature of the donor cells.
Separate plates spread plated with 200 ml of donor and recipient
cells were also included as controls. Sensitivity of plasmid transfer
to DNaseI was tested by treating 1 ml of donor cells with DNaseI
(100 mg/ml) in a buffer containing 20 mM Tris-HCl, pH 7.5,
1 mM MgCl2 and 1 mM MgSO4 for 37uC for 60 minutes [42].
On the nonselective agar plate 25 ml of DNaseI (10 mg/ml) and
50 ml of 50 mM MgSO4 were added, spread evenly and the plates
were incubated at room temperature for 60 minutes. Donor cells
incubated for 60 min with DNaseI, were spun down at 3,0006g
for 5 min. The supernatant was discarded and the cell pellet was
re-suspended in 200 ml of the recipient strain. DNaseI (100 mg/ml)
and 1 mM MgSO4 were added to the cell mixture and the cells
were spread plated onto the TYG agar supplemented with DNaseI
and MgSO4. The plates were incubated at 37uC for 12 h.
Mating experiments were also performed by separating the
donor and recipient cells with a 0.45 mm nitrocellulose membrane
to determine if cell-to-cell contact is required for plasmid transfer.
In these experiments 200 ml of the donor cell suspensions were
spotted in the middle of the plate and spread slightly, and plates
incubated until all moisture was absorbed. Then nitrocellulose
membrane was placed on top of the donor cells, the plates
incubated until the membrane completely adhered to the agar,
followed by spreading the recipient cells in the middle of the
membrane. The mating plates were incubated right side up for
12 hours at 37uCo r3 0 uC. The recipient cells were then scraped
off the surface of the membrane using cell scrapers, the cells were
resuspended in the PBS and plated on selective plates.
To assess the possible involvement of bacteriophages in plasmid
transfer, donor cell cultures were passed through a 0.45 mm filter
(Millipore) and mixed 1:1 with the recipient cell culture [43].
CaCl2 (1mM) was added and the mixture was incubated for 12 h
at 37uC.
Following matings the controls and mating mixtures were
scraped off of the TYG agar plates and re-suspended in 3 ml of
sterile 16PBS, serially diluted and plated in duplicate on TYG
agar supplemented with tetracycline and erythromycin for
selection of the transconjugants. Serial dilutions were also spread
plated onto TYG supplemented with tetracycline for enumeration
of recipients and transconjugants and TYG containing eythromy-
cin for enumeration of donors and transconjugants. The plates
were incubated anaerobically for 3 days at 30uCo r3 7 uC. The
plasmid transfer frequency was calculated as the number of
transconjugants per number of donor cells in matings in which the
number of donors was greater than the number of recipients.
Transfer frequencies were calculated as the number of transcon-
jugants per number of recipient cells when the recipient counts
were greater than the donor cell counts.
Colonies resistant to both tetracycline and erythromycin were
re-streaked for isolation onto fresh TYG agar supplemented with
tetracycline and erythromycin and kept for further analysis.
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Confirmation of plasmid transfer was performed by pulsed-field
gel electrophoresis (PFGE) of nondigested and digested DNA of
the transconjugant, donor and recipient strains. C. botulinum strains
were inoculated into 10 ml of TPGY and incubated anaerobically
at 37uC (proteolytic strains) or 30uC (nonproteolytic strains) to an
optical density at 600 nm (OD600) of 0.6. One milliliter of
formaldehyde (Fisher Scientific, Hampton, NH) was added, and
the cultures were placed on ice for 15 to 30 minutes to inhibit
nuclease activity. PFGE plugs were prepared as described by
Johnson et al. [44].
To increase the visualization of plasmids, pBotCDC-A3-Erm,
pCLJ-Erm and pCLL-Erm in the LNT01 transconjugant clones,
restriction digests of PFGE plugs were performed using restriction
endonucleases chosen to linearize each plasmid. The nucleotide
sequences of each plasmid were analyzed using VectorNTI version
10.3 (Invitrogen, Carlsbad, CA) and a rare cutting restriction
enzyme that cleaves the plasmid once was selected. Restriction
enzymes SmaI, XhoI and NarI (New England Biolabs), were selected
to digest the PFGE plugs of LNT01 transconjugants to assess the
presence of plasmids pBotCDC-A3-Erm, pCLJ-Erm and pCLL-
Erm, respectively. Restriction digests of the PFGE plugs were
performed according to the manufacturer’s instructions (New
England Biolabs). Two sets of nondigested and digested DNA
samples were loaded on the same gel and DNA samples were
separated by PFGE in a clamped homogenous electric field system
(CHEF-DRII; Bio-Rad, Hercules CA). After the DNA was
transferred onto the nylon membrane, the filter was cut in a half,
and each portion contained one set of undigested and digested
DNA samples. One membrane was hybridized with a neurotoxin
gene specific probe, while the other with an erythromycin gene
probe.
Southern Hybridizations
Primers for generation of hybridization probes for ermB (ErmF
and ErmR); bont/A3 (A3KMCT1 and A3KMCT2); bont/bvB and
bont/npB (AnyB-F and AnyB-R) are listed in Table 1. These gene
probes were generated by PCR amplification with an AmpliTaq
High Fidelity DNA polymerase, buffer and dNTPs (Applied
Biosystems, Foster City, CA) using a GeneAmp PCR System 9700
(Applied Biosystems) according to the manufacturer’s instructions.
The PCR products were purified from agarose gels using the
Qiagen gel extraction kit (Qiagen, Valencia, CA), and were
radioactively labeled with [a-
32P] ATP using the Megaprime DNA
labeling system (GE Healthcare Bio-Sciences, Piscataway, NJ).
The DNA samples separated by PFGE were transferred to a
positively charged nylon membrane (Immobilon-NY+, Millipore,
Bedford, MA) overnight by downward capillary transfer in 0.4 M
NaOH, 1.5 M NaCl. The membranes were neutralized in 2 M
Tris-HCl, pH 7.0 for 15 minutes, rinsed with 26SSC (3M NaCl,
0.3M sodium citrate) and fixed at 80uC for 30 minutes under
vacuum.
Hybridizations were performed at 42uC for 16 h in a solution
containing 56 Denhardt’s Solution, 66SSPE, 50% formamide,
0.1% SDS, 100 mg/ml herring sperm DNA (Promega, Madison,
WI) and
32P-labeled probes at ,2610
6 cpm/ml. All hybridization
solutions and buffers were prepared according to standard
protocols [41]. After hybridizations the membranes were washed
twice with 26SSPE, 0.1% SDS for 5 min each at room
temperature and twice with 0.16SSPE, 0.1% SDS for 30 min
each at 42uC. Autoradiography of the membranes was performed
for 6–24 h at 270uC using Kodak BioMax MS film with a
BioMax intensifying screen (Eastman Kodak, Rochester, NY).
Plasmid Alignments
Plasmid sequence alignments were performed to determine the
relatedness of the plasmid pCLL [Acc. No. CP001057] in C.
botulinum strain Eklund 17B to plasmids, pCP13 [Acc.
No. P003515] of C. perfringens strain 13, pCW3 [Acc
No. DQ366035] of C. perfringens strain CW92, pCP8533etx [Acc.
No. AB444205] of C. perfringens strain NCTC8533B4D, and two
contigs, gcontig_1108490430999 [Acc. No. ABOO01000010.1]
and gcontig_1108490430283 [Acc. No ABOO01000017] of C.
perfringens type D strain JGS1721. Plasmid sequence files with
annotations were obtained from NCBI. Plasmid alignments were
conducted using progressive alignment option of Mauve 2.3.1 [29]
with the default settings. Figures 7 and 8 were generated using the
Mauve alignment viewer, which illustrates locally collinear blocks
(LCBs) as regions without rearrangements in the homologous
backbone sequence. LCBs below a plasmid’s center line represent
the reverse complement orientation relative to the reference
genome (pCP13, Fig. 7; pCLL, Fig. 8). Sequence similarity plots
are displayed in the LCBs, and the height of the sequence identity
plot reflects the average column entropy for the region of the
respective alignment. The NCBI blastp tool was used to compare
the amino acid sequences of the pCLL ORFs with ORFs in C.
perfringens strains.
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